期刊文献+

化学键合紫杉醇纳米微粒对Lewis肺癌细胞株的增殖抑制作用 被引量:6

Inhibition of the proliferation of Lewis lung cancer cells by PEG-PLA-paclitaxel conjugate micelles nanometer particle
下载PDF
导出
摘要 目的探讨两亲性生物降解材料聚乳酸-聚乙二醇(MPEG-PLA)键合紫杉醇(paclitaxel)纳米微粒对Lewis肺癌细胞株的增殖抑制作用。方法应用透析方法制备化学键合的紫杉醇纳米粒子,并用动态激光光散射(DLS)测定其粒径和扫描电镜观察其形态,通过MTT法测定和比较键合紫杉醇纳米微粒与紫杉醇对Lewis肺癌细胞株的增殖抑制作用。结果键合紫杉醇纳米粒子的粒径分布基本呈现单一对称分布,能够形成球状,其和紫杉醇相比较,对Lewis肺癌细胞株的增殖具有抑制作用,并且具有浓度和时间依赖性,随药物作用时间和浓度的增大,抑制率逐渐增高。结论两亲性生物可降解材料聚乳酸-聚乙二醇(MPEG-PLA)键合紫杉醇(paclitaxel)纳米微粒,与紫杉醇同样具有抗癌活性,可做为肺癌靶向治疗的新型制剂。 Objective To study the inhibitory effect of PEG - PLA - paeiitaxel conjugate micelles nanometer particle against lewis lung cancer. Methods PEG - PLA - paclitaxel conjugate micelles nanometer particle was generated by dialysis and its physicochemical characteristicss were evaluated by dynamic laser light scattering (DLS) and scanning electron microscope (SEM). Antitumor activities against lewis lung cancer cells were evaluated by MTT method. Results The nanometer particle assumed a spherical shape and had a unimodal size distribution. It had a sustained antitumor activity against lewis lung cancer cells in a time - and dose - dependent manner. Conclusion PEG - PLA - paclitaxel conjugate nanometer particle had a sustained antitumor activity against lewis lung cancer cells similarto paclitaxel. It can be used as a new fargeted therapy for lung cancer.
出处 《广东医学》 CAS CSCD 北大核心 2007年第2期175-177,共3页 Guangdong Medical Journal
基金 国家自然科学基金资助项目(编号:20274048)
关键词 紫杉醇 肺癌 靶向治疗 Paclitaxel Lung cancer Targeted therapy
  • 相关文献

参考文献8

二级参考文献14

  • 1赵家美,廖美琳,徐扣凤.MAP治疗非小细胞肺癌的疗效分析[J].实用肿瘤杂志,1993,8(4):209-211. 被引量:15
  • 2阎家麒,童岩,王九一.紫杉醇脂质体的制备及其抑瘤作用的研究[J].药物生物技术,1996,3(3):154-157. 被引量:40
  • 3陈新谦 金有豫.新编药物学(第十四版)[M].北京:人民卫生出版社,1994.522.
  • 4王家明,中国新药杂志,1995年,4卷,增刊,11页
  • 5韩锐,肿瘤化学预防及药物治疗,1991年,278页
  • 6胥彬,医药工业杂志,1985年,16卷,12期,551页
  • 7ANDERSON N G, AHMAD T, CHAN K, et al. ZD1839(IRESSA), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,potently inhibits the growth of EGFR- positive cancer cell lines with or without erbB2 overexpression[J]. Int J Cancer, 2001,94(6):774 - 782.
  • 8FUKUOKA M,YANO S,GIACCONE G,et al. Multi- institutional randomized phase Ⅱ trial of Gefinititibfor previously treated patients with advanced non - smalll cell lung cancer[J]. J Clin Oncol, 2003, 21 :2237 - 2246.
  • 9KRIS M G, NATALE RS, HERBST R S,et al. Efficacy of Gefinitib,an inhibitor of the epidermal growth factor tyrosine kinase in symptomatic patients with non - smalll cell lung cancer[J]. JAMA,2003,290:2149- 2158.
  • 10CIACCONE C, JOHNSON D H, MANEGOLD C, et al. A phase Ⅲ clinical trial of ZD1839(Iressa) in combination with gemcitabine and cisplatin in chemotherapy - naYve patients with advanced non - small cell lung eancer(INTXCTI)[J]. Ann Oncol, 2002,13(Suppl 5):2a.

共引文献27

同被引文献95

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部